查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405775

癫痫药物市场规模、份额、趋势分析报告：按产品、地区、细分市场预测，2023-2030

Epilepsy Drugs Market Size, Share & Trends Analysis Report By Product (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics), By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 91 Pages | 商品交期: 2-10个工作天内

价格

癫痫药物市场成长与趋势：

Grand View Research, Inc.最新报告显示，预计2030年全球癫痫药物市场规模将达到153.5亿美元，2023年至2030年复合年增长率为5.1%。

增加政府对有效治疗癫痫发作的新药市场开拓的资助是癫痫药物市场成长的重要动力。美国癫痫协会 (AES) 与美国神经病学学会、癫痫基金会和格拉斯基金会等其他组织合作，为研究和开发活动提供资金。透过各种方式向医生提供护理意识培训。的程序。

此外，癫痫基金会、美国癫痫协会、佛罗里达州中部癫痫协会、CURE Epilepsy 和 Anita Kaufmann 基金会等组织所进行的各种提高认知计画正在进一步加速诊断和治疗速度。预计这将在预测期内推动市场成长。

癫痫药物市场报告亮点

  • 第二代抗癫痫药物预计将成为成长第二快的细分市场。此细分市场包括拉莫三嗪（Lamictal）、左乙拉西坦（Keppra）、布瓦西坦（Briviact）、吡崙帕奈（Fycompa）等。
  • 第三代抗癫痫药细分市场占最大销售份额，2022年约39.3%。促进该领域成长的主要因素包括作用机制改进、副作用更少的高效药物的推出，以及新管道药物的等待名单。
  • 2022年，北美地区的销售份额最高，约45%，占据市场主导地位。该地区癫痫的高盛行率和大量受影响的人是癫痫药物市场的主要推动要素。
  • 据估计，亚太地区在预测期内的复合年增长率将达到 6.3%，增幅最高。癫痫部门间全球行动计划、全球抗癫痫宣传活动以及新一代抗癫痫药物的推出等政府倡议的存在预计将成为推动该地区市场成长的因素。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章 市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 普及和成长前景图
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 普及和成长前景图
  • 全球癫痫药物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章 癫痫药物市场：产品评估与趋势分析

  • 癫痫药物市场：重点
  • 癫痫药物市场：2022 年和 2030 年产品趋势和市场占有率分析
  • 第一代抗癫痫药
  • 第二代抗癫痫药
  • 第三代抗癫痫药

第五章 癫痫药物市场：按药物分類的区域估计和趋势分析

  • 区域展望
  • 按地区分類的癫痫药物市场：市场要点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 沙乌地阿拉伯
    • 南非
    • 阿拉伯聯合大公国
    • 科威特

第六章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • 比利时 UCB SA
    • 赛诺菲
    • 辉瑞日本公司
    • 大冢美国製药股份有限公司
    • Eisai
    • 诺华公司
    • 雅培实验室公司
    • 赛诺菲亚万蒂斯公司
    • GlaxoSmithKline Plc公司
    • 尚诺维製药有限公司
    • 爵士製药公司
    • 新瑞利斯有限公司
Product Code: 978-1-68038-958-6

Epilepsy Drugs Market Growth & Trends:

The global epilepsy drugs market size is expected to reach USD 15.35 billion by 2030, registering a CAGR of 5.1% from 2023 to 2030, according to a new report by Grand View Research, Inc. The rising government funding for the development of new and effective drugs for the treatment of seizures is a high impact rendering driver for the epilepsy drugs market growth. The American Epilepsy Society (AES) in alliance with other organizations, such as American Academy of Neurology, the Epilepsy Foundation, and the Grass Foundation, provide funding for R&D activities and offer treatment line awareness trainingto the physicians through different programs.

Furthermore, various awareness programs conducted by organizations, such as the Epilepsy Foundation, the American Epilepsy Society, Epilepsy Association of Central Florida, CURE Epilepsy, and the Anita Kaufmann Foundation, further accelerate the diagnosis and treatment rates. This is expected to propel the market growth over the forecast period.

Epilepsy Drugs Market Report Highlights:

  • Second generation anti-epileptics are expected to be the second-fastest-growing segment. This segment includes Lamotrigine (Lamictal), Levetiracetam (Keppra), Brivaracetam (Briviact), and Perampanel (Fycompa).
  • The third generation anti-epileptics segment accounted for the largest revenue share of around 39.3% in 2022. The major factors responsible for the growth of this segment include the launch of high efficacy drugs with improved mechanism of action and fewer side effects, and the awaited launch of new pipeline drugs.
  • North America dominated the market with the largest revenue share of around 45% in 2022. The high prevalence of epilepsy in the region, with a significant number of people affected by the condition, is a major driving factor for the epilepsy drugs market.
  • Asia Pacific is estimated to expand at the highest CAGR of 6.3% over the forecast period. The presence of favorable government initiatives such as the Intersectoral Global Action Plan on Epilepsy, Global Campaign Against Epilepsy, and others, as well as the launch of new-generation anti-epileptic drugs are the drivers expected to propel the growth of this market in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Product
    • 1.1.2. Regional scope
    • 1.1.3. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives
    • 1.9.1. Objective 1
    • 1.9.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product outlook
    • 2.2.2. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. Penetration & Growth Prospect Mapping
  • 3.5. Global Epilepsy Drug Market Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
      • 3.5.2.1. Political landscape
      • 3.5.2.2. Technological landscape
      • 3.5.2.3. Economic landscape

Chapter 4. Epilepsy Drugs Market: Product Estimates & Trend Analysis

  • 4.1. Epilepsy Drug Market: Key Takeaways
  • 4.2. Epilepsy Drug Market: Product Movement & Market Share Analysis, 2022 & 2030
  • 4.3. First Generation Anti-epileptics
    • 4.3.1. First generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Second Generation Anti-epileptics
    • 4.4.1. Second generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Third Generation Anti-epileptics
    • 4.5.1. Third generation anti-epileptics market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Epilepsy Drugs Market: Regional Estimates & Trend Analysis, by Drug

  • 5.1. Regional Outlook
  • 5.2. Epilepsy Drug Market by Region: Key Marketplace Takeaways
  • 5.3. North America
    • 5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.2. U.S.
      • 5.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.3.3. Canada
      • 5.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.4. Europe
    • 5.4.1. UK
      • 5.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.2. Germany
      • 5.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.3. France
      • 5.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.4. Italy
      • 5.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.5. Spain
      • 5.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.6. Sweden
      • 5.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.7. Norway
      • 5.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.4.8. Denmark
      • 5.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.5. Asia Pacific
    • 5.5.1. Japan
      • 5.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.2. China
      • 5.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.3. India
      • 5.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.4. Australia
      • 5.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.5. Thailand
      • 5.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.5.6. South Korea
      • 5.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.6. Latin America
    • 5.6.1. Brazil
      • 5.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.2. Mexico
      • 5.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.6.3. Argentina
      • 5.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 5.7. MEA
    • 5.7.1. Saudi Arabia
      • 5.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.2. South Africa
      • 5.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.3. UAE
      • 5.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 5.7.4. Kuwait
      • 5.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. UCB S.A., Belgium
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Financial Performance
      • 6.2.1.3. Product Benchmarking
      • 6.2.1.4. Strategic Initiatives
    • 6.2.2. Sanofi
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Financial Performance
      • 6.2.2.3. Product Benchmarking
      • 6.2.2.4. Strategic Initiatives
    • 6.2.3. Pfizer, Inc.
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Financial Performance
      • 6.2.3.3. Product Benchmarking
      • 6.2.3.4. Strategic Initiatives
    • 6.2.4. Otsuka America Pharmaceutical, Inc.
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Financial Performance
      • 6.2.4.3. Product Benchmarking
      • 6.2.4.4. Strategic Initiatives
    • 6.2.5. Eisai Co., Ltd.
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Performance
      • 6.2.5.3. Product Benchmarking
      • 6.2.5.4. Strategic Initiatives
    • 6.2.6. Novartis AG
      • 6.2.6.1. Company Overview
      • 6.2.6.2. Financial Performance
      • 6.2.6.3. Product Benchmarking
      • 6.2.6.4. Strategic Initiatives
    • 6.2.7. Abbott Laboratories, Inc.
      • 6.2.7.1. Company Overview
      • 6.2.7.2. Financial Performance
      • 6.2.7.3. Product Benchmarking
      • 6.2.7.4. Strategic Initiatives
    • 6.2.8. Sanofi Aventis S.A.
      • 6.2.8.1. Company Overview
      • 6.2.8.2. Financial Performance
      • 6.2.8.3. Product Benchmarking
      • 6.2.8.4. Strategic Initiatives
    • 6.2.9. GlaxoSmithKline plc
      • 6.2.9.1. Company Overview
      • 6.2.9.2. Financial Performance
      • 6.2.9.3. Product Benchmarking
      • 6.2.9.4. Strategic Initiatives
    • 6.2.10. Sunovion Pharmaceuticals, Inc.
      • 6.2.10.1. Company Overview
      • 6.2.10.2. Financial Performance
      • 6.2.10.3. Product Benchmarking
      • 6.2.10.4. Strategic Initiatives
    • 6.2.11. Jazz Pharmaceuticals plc
      • 6.2.11.1. Company Overview
      • 6.2.11.2. Financial Performance
      • 6.2.11.3. Product Benchmarking
      • 6.2.11.4. Strategic Initiatives
    • 6.2.12. Neurelis, Inc.
      • 6.2.12.1. Company Overview
      • 6.2.12.2. Financial Performance
      • 6.2.12.3. Product Benchmarking
      • 6.2.12.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 3 North America epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 4 U.S. epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 5 Canada epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 6 Europe epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 7 Europe epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 8 Germany epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 9 UK epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 10 France epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 11 Italy epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 12 Spain epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 13 Sweden epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 Norway epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 15 Denmark epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 16 Asia Pacific epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 17 Asia Pacific epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 18 China epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 19 Japan epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 20 India epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 21 Thailand epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 22 Australia epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 23 South Korea epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 24 Latin America epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 25 Latin America epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 26 Brazil epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 27 Mexico epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 28 Argentina epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 29 Middle East and Africa epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 30 Middle East and Africa epilepsy drugs market, by country, 2018 - 2030 (USD Million)
  • Table 31 South Africa epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 32 Saudi Arabia epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 UAE epilepsy drugs market, by product, 2018 - 2030 (USD Million)
  • Table 34 Kuwait epilepsy drugs market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Epilepsy drug market: Market outlook
  • Fig. 9 Epilepsy drug market: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Epilepsy drug market driver impact
  • Fig. 15 Epilepsy drug market restraint impact
  • Fig. 16 Epilepsy drug market strategic initiatives analysis
  • Fig. 17 Epilepsy drug market: Product movement analysis
  • Fig. 18 Epilepsy drug market: Product outlook and key takeaways
  • Fig. 19 First generation anti-epileptics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Second generation anti-epileptics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Third generation anti-epileptics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Global epilepsy drug market: Regional movement analysis
  • Fig. 23 Global epilepsy drug market: Regional outlook and key takeaways
  • Fig. 24 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 40 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)